Skip to main content
. Author manuscript; available in PMC: 2012 Nov 1.
Published in final edited form as: Stroke. 2011 Sep 8;42(11):3168–3175. doi: 10.1161/STROKEAHA.111.620831

Table 4.

Absolute Change in Blood Pressure, Weight and Plasma Lipids, Glucose and Isoflavone Levels

Placebo ISP p-value*
Total Cholesterol – mg/dl −0.1 (−4.6-4.3) −1.4 (−5.4-2.5) 0.55
HDL-Cholesterol – mg/dl 1.3 (0.2-2.5) 2.7 (1.4-3.9) 0.03
LDL-Cholesterol – mg/dl −2.3 (−6.7-2.0) −4.0 (−7.8- −0.2) 0.41
Total Triglycerides – mg/dl 8.0 (−3.5-19.4) 1.6 (−6.3-9.5) 0.09
Plasma genistein – nmol/L −7.5 (−76.7-61.7) 467.1 (366.4-567.8) <.0001
Plasma daidzein – nmol/L 11.8 (−36.3-59.8) 337.9 (273.5-402.3) <.0001
Plasma glycitein – nmol/L 2.9 (−0.04-5.9) 10.3 (7.3-13.3) 0.0002
Glucose – mg/dl −2.7 (−4.4- −0.9) −0.8 (−2.7-1.0) 0.12
Systolic Blood Pressure – mmHg −1.7 (−3.7-0.3) −2.3 (−4.3- −0.3) 0.51
Diastolic Blood Pressure – mmHg −2.0 (−3.5- −0.6) −2.5 (−4.0- −1.0) 0.53
Weight – lbs 0.3 (−0.9-1.6) 0.4 (−0.8-1.5) 0.93
*

Mean (95% confidence interval) change from baseline, adjusted for randomization stratum.

Treatment groups compared using generalized estimating equations with identity link function and exchangeable correlation structure.

Median (25th, 75th percentile) for change from baseline variables with non-normal distributions:
  • Total triglycerides: Placebo = 2.5 (−14.5, 21.0); ISP = 1.0 (−19.5, 19.0).
  • Plasma genistein: Placebo = 0.6 (−6.1, 21.2); ISP = 273.9 (70.3, 679.3).
  • Plasma daidzein: Placebo = 2.1 (−6.4, 28.3); ISP = 202.9 (49.9, 484.9).
  • Plasma glycitein: Placebo = 0.0 (−0.6, 2.1); ISP = 4.2 (0, 14.3).

ISP = isoflavone soy protein treatment group.